Investigation Report on China's Linezolid Market 2021-2025

Investigation Report on China’s Linezolid Market 2021-2025

$2600 – $3900

In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Linezolid in the Chinese market fell to CNY695 million in 2020, a year-on-year decrease of 14.89%.

SKU: 2107536 Category: Tags: , , , , , , , , , , , , , , , , , , , ,

Description

Linezolid is an oxazolidinone antibiotic, mainly used to treat infections caused by gram-positive (G+) cocci, including suspected or confirmed hospital-acquired pneumonia (HAP) caused by methicillin-resistant Staphylococcus aureus (MRSA), community-acquired pneumonia (CAP), complex skin or skin and soft tissue infections (SSTI), and vancomycin-resistant enterococcus (VRE) infections. Linezolid’s product ZYVOX was developed by Pfizer Pharmaceuticals. It was approved to enter the Chinese market in 2006. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, by 2020, there are several manufacturers besides Pfizer in the Linezolid market in China.

According to CRI’s market research, the sales value of Linezolid in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Linezolid in the Chinese market fell to CNY695 million in 2020, a year-on-year decrease of 14.89%. However, the CAGR of Linezolid sales value in the Chinese market from 2016 to 2020 is still 14.45%.

CRI expects that with the relief of COVID-19, the sales value of Linezolid in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Linezolid has high antibacterial activity against Staphylococcus, Streptococcus pneumoniae, and Enterococcus bacteria, and has no cross-resistance with other antibacterial drugs. It is currently the first choice for the treatment of severe infections such as septic shock. These advantages make sales value and sales volume have room to rise.

 

Topics Covered:

  • -The impact of COVID-19 on China’s Linezolid market
  • – Sales value of China’s Linezolid 2016-2020
  • – Competitive landscape of China’s Linezolid market
  • – Prices of Linezolid in China
  • – Prices of Linezolid in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Linezolid market
  • – Prospect of China’s Linezolid market from 2021 to 2025

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format

Base Year

2016
Base Market Size

405.30
Currency/Unit

CNY million
Forecast Year

2025
Market Size Forecast

1398.90
CAGR

14.76%

Table of Contents

1 Relevant Concepts of Linezolid

  • 1.1 Indications for Linezolid
  • 1.2 Development of Linezolid in China
  • 1.3 Governmental Approval of Linezolid in China
  • 1.4 The Impact of COVID-19 on Linezolid Sales in China

 

2 Sales of Linezolid in China, 2016-2020

  • 2.1 Sales Value of Linezolid
  • 2.1.1 Overall Sales Value
  • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Linezolid
  • 2.2.1 Overall Sales Volume
  • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Linezolid by Dosage Form in China, 2016-2020
  • 2.3.1 Injection
  • 2.3.3 Tablets

 

3 Analysis of Major Linezolid Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Linezolid Manufacturers
  • 3.1.1 Investigation on Market Share by Sales Value
  • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Pfizer AS
  • 3.2.1 Enterprise Profile
  • 3.2.2 Sales of ZYVOX (Pfizer AS’s Linezolid) in China
  • 3.3  Jiangsu Hausen Pharmaceutical Group Co., Ltd.
  • 3.3.1 Enterprise Profile
  • 3.3.2 Sales of Hengjie (Jiangsu Hausen Pharmaceutical Group Co., Ltd.’s Linezolid) in China
  • 3.4 Pfizer Inc
  • 3.4.1 Enterprise Profile
  • 3.4.2 Sales of ZYVOX (Pfizer Inc ’s Linezolid) in China
  • 3.5 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • 3.5.1 Enterprise Profile
  • 3.5.2 Sales of Tianli (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Linezolid) in China
  • 3.6 Chongqing Winbond Pharmaceutical Co., Ltd.
  • 3.6.1 Enterprise Profile
  • 3.6.2 Sales of Feikangning (Chongqing Winbond Pharmaceutical Co., Ltd.’s Linezolid) in China

 

4 Prices of Linezolid for Different Manufacturers in China, 2020-2021

  • 4.1 Pfizer AS (ZYVOX)
  • 4.2 Jiangsu Hausen Pharmaceutical Group Co., Ltd.  (Hengjie)
  • 4.3 Pfizer Inc (ZYVOX)
  • 4.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianli)
  • 4.5 Chongqing Winbond Pharmaceutical Co., Ltd. (Feikangning)

 

5 Prospect of Chinese Linezolid Market, 2021-2025

  • 5.1 Influential Factors of Chinese Linezolid Market Development
  • 5.1.1 The Impact of COVID-19 on Chinese Linezolid Market
  • 5.1.2 Market Drivers and Opportunities
  • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

 

List of Charts

  • Chart Patent Information About Linezolid Injection Registration in China
  • Chart Patent Information About Linezolid Tablets Registration in China
  • Chart Sales Value of Linezolid Injection over the World
  • Chart Sales Value of Linezolid Tablets over the World
  • Chart Sales Value of Linezolid Injection in China, 2016-2020
  • Chart Sales Value of Linezolid Tablets in China, 2016-2020
  • Chart Sales Value of Linezolid Injection in China by Region, 2016-2020
  • Chart Sales Value of Linezolid Tablets in China by Region, 2016-2020
  • Chart Sales Volume of Linezolid Injection in China, 2016-2020
  • Chart Sales Volume of Linezolid Tablets in China, 2016-2020
  • Chart Sales Volume of Linezolid Injection in China by Region, 2016-2020
  • Chart Sales Volume of Linezolid Tablets in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Linezolid Injection Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Linezolid Tablets Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of ZYVOX (Pfizer AS’s Linezolid) in China, 2016-2020
  • Chart Sales Value and Volume of Hengjie in China, 2016-2020
  • Chart Sales Value and Volume of ZYVOX (Pfizer Inc’s Linezolid) in China, 2016-2020
  • Chart Sales Value and Volume of Tianli in China, 2016-2020
  • Chart Sales Value and Volume of Feikangning in China, 2016-2020
  • Chart Referential Prices of ZYVOX (Pfizer AS’s Linezolid) in China by Region, 2020-2021
  • Chart Referential Prices of Hengjie in China by Region, 2020-2021
  • Chart Referential Prices of ZYVOX (Pfizer Inc’s Linezolid) in China by Region, 2020-2021
  • Chart Referential Prices of Tianli in China by Region, 2020-2021
  • Chart Referential Prices of Feikangning in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Linezolid Injection in China, 2021-2025
  • Chart Forecast on Sales Value of Linezolid Tablets in China, 2021-2025
  • Chart Forecast on Sales Volume of Linezolid Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Linezolid Tablets in China, 2021-2025

Related products